Table 5.
rhIL21 induced IL2RA expression in whole blood from cynomolgus monkeys dosed with Ab-01
| Animal | Treatment Group | Time point | Ex vivoIL2RA Fold Change Response to IL21 Stimulation | Cpeak |
|---|---|---|---|---|
| 1 | Ab-01 | pre-dose | 2.8 | not applicable |
| 1 | Ab-01 | 5 minute post dose | 0.8 | 200 |
| 2 | Ab-01 | pre-dose | 4.8 | not applicable |
| 2 | Ab-01 | 5 minute post dose | 0.8 | 139 |
| 3 | Ab-01 | pre-dose | 4.2 | not applicable |
| 3 | Ab-01 | 5 minute post dose | 0.9 | 153 |
| 4 | Control IgG1TM | pre-dose | 4.2 | not applicable |
| 4 | Control IgG1TM | 5 minute post dose | 4.3 | not applicable |
| 5 | Control IgG1TM | pre-dose | 2.7 | not applicable |
| 5 | Control IgG1TM | 5 minute post dose | 4.4 | not applicable |
| 6 | Control IgG1TM | pre-dose | 9.1 | not applicable |
| 6 | Control IgG1TM | 5 minute post dose | 7.7 | not applicable |
Relative RNA concentration of IL2RA induced by ex vivo addition of rhIL-21 to whole blood obtained from cynomolgus monkeys before and after treatment with either Ab-01 or control IgG1TM is shown. Pre-dose whole blood sample was taken on day -13 for animal 1, and on day 0 (the day of dosing) for all others. All monkeys were dosed with 10 mg/kg via intravenous (IV) route. The ex vivo response to IL21 was completely blocked in monkeys treated with Ab-01 and was not blocked in control IgG1TM treated monkeys